Micro cap Heat Biologics (NASDAQ:HTBX) jumps 24% premarket on increased volume on the heels of encouraging preclinical data on its gp96-based COVID-19 vaccine candidate.
The results, generated at the University of Miami Miller School of Medicine, showed a robust T cell-mediated immune response against the SARS-CoV-2 spike protein. Specifically, the vaccine induced responses in both “killer” CD8+ T cells and “helper” CD4+ T cells.
The results from the animal studies will be published in the coming weeks.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.